BrainStorm Hoping For Advisory Committee After FDA Refuses To File BLA For Its ALS Cell Therapy

 
• By Derrick Gingery
  
ALS neurons
A confirmatory trial is one possibility that BrainStorm will discuss with the FDA following NurOwn's refuse-to-file letter. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards